Delving into the Latest Updates on Zymetx, Inc. with Synapse

概览

关联

11

项与 Zymetx, Inc. 相关的药物

ZX-0791

靶点

neuraminidase

作用机制

neuraminidase抑制剂

在研机构-

原研机构

Zymetx, Inc.

在研适应症-

非在研适应症

流感病毒感染

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

ZX-0851

靶点

RNA

作用机制

RNA抑制剂

在研机构-

原研机构

Oklahoma Medical Research Foundation

在研适应症-

非在研适应症

HIV感染

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

ZX-1293

靶点

ACE

作用机制

ACE抑制剂

在研机构-

原研机构

Zymetx, Inc.

在研适应症-

非在研适应症

单纯疱疹

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

100 项与 Zymetx, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Zymetx, Inc. 相关的专利（医药）

登录后查看更多信息

12

项与 Zymetx, Inc. 相关的文献（医药）

2005-11-01·Antiviral Research2区 · 医学

Broad-spectrum inhibitor of viruses in the Flaviviridae family

2区 · 医学

Article

作者: Smee, Donald F. ; Ojwang, Joshua O. ; Ali, Shoukath ; Shimasaki, Craig D. ; Sidwell, Robert W. ; Morrey, John D.

The viruses in the Flaviviridae family have been associated with human and animal diseases. In this report, we demonstrate that compound 2-amino-8-(beta-D-ribofuranosyl) imidazo [1,2-a]-s-triazine-4-one (ZX-2401) was capable of inhibiting the production in culture of at least five members of the Flaviviridae family with minimal cytotoxicity. This compound inhibited yellow fever virus, dengue virus, bovine viral diarrhea virus, banzi virus and West Nile virus with EC50 of 10, 10, 5, 5 and 3 microg/ml, respectively, and the CC50 in these experiments were greater than 1000 microg/ml. The activity of ZX-2401 is comparable to or better than the control drugs in these studies and was not affected by MOI variation. In addition, ZX-2401 inhibited HCV replication in a dose response fashion in the replicon assay system. Furthermore, ZX-2401 exhibited a synergistic antiviral activity in combination with IFN in tissue culture. The data described herein suggest that ZX-2401 is a broad-spectrum inhibitor of the RNA viruses, which has merit for development of treatments for the emerging infections caused by the viruses in the Flaviviridae family.

2004-09-01·Journal of Medical Virology4区 · 医学

New point of care test is highly specific but less sensitive for influenza virus A and B in children and adults

4区 · 医学

Article

作者: Zubair M. Waliuzzaman ; William D. Rawlinson ; James R. Appleman ; Michael Fennell ; Ian W. Carter ; Craig D. Shimasaki

AbstractThe importance of rapid diagnosis of influenza has increased with the availability of neuraminidase inhibitors, which need to be commenced within 48 hr of symptom onset. Furthermore, the recent development of influenza‐like clinical syndromes with novel aetiologies (severe acute respiratory syndrome, SARS) has increased the need for rapid and accurate near‐patient diagnosis. A new, modified point of care (POC) diagnostic test (ZstatFlu) was assessed on 469 nasopharyngeal aspirates (NPAs) and 260 nose/throat swabs (TS) taken from children and adults. The test was specific (77–98%) for all specimen types for influenza virus A and B, depending upon incubation conditions. However, it was less sensitive, detecting 65–77% of specimens confirmed as positive on culture, direct immunofluorescence or PCR testing. A positive test is useful, for both directing initiation of therapy in the clinician's office, and making a positive diagnosis of influenza in patients with influenza‐like clinical syndromes. J. Med. Virol. 74:127–131, 2004. © 2004 Wiley‐Liss, Inc.

2003-05-01·Luminescence4区 · 化学

ZstatFlu®‐II test: a chemiluminescent neuraminidase assay for influenza viral diagnostics

4区 · 化学

Article

作者: Craig D. Shimasaki ; Komandoor E. Achyuthan ; James R. Appleman ; Lisa M. Pence

AbstractThe ZstatFlu®‐II test is a highly sensitive, specific, rapid, point‐of‐care chemiluminescent diagnostic test for influenza infection. Influenza viral neuraminidase‐specific substrate, spiroadamantyl‐1,2‐dioxetane‐4,7‐dimethoxy‐N‐acetyl‐neuraminic acid, is at the core of the ZstatFlu®‐II Test. The enzymatic reaction was carried out at 25°C and neutral pH, representing the optimum assay conditions for influenza types A and B viral neuraminidases. The results were outputted on a Polaroid™ High Speed Detector Film. Positive results appeared as a ‘+’‐shaped white film image; negative results produced no image. The ‘glow’ kinetics, facilitated by a unique combination of light enhancers, also ‘tuned’ the wavelength of emission to match the spectral properties of the film. The substrate hydrolysed non‐enzymatically at acid pH or at temperatures above 25°C. In order to minimize false positives, the ZstatFlu®‐II Test was formatted with 0.3–0.4 Km substrate and freezing the test kit until use. The pH optimization of the ZstatFlu®‐II test is discussed with reference to model compounds of sialyl‐glycosides. A nucleophilic attack or an electrostatic stabilization of a developing carbonium ion under the influence of the adjacent carboxyl group was probably responsible for non‐enzymatic hydrolysis of the substrate. Intramolecular general acid catalysis is proposed as a mechanism for the lability of the O‐glycosidic linkage of the substrate. Copyright © 2003 John Wiley & Sons, Ltd.

100 项与 Zymetx, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Zymetx, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

11

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

ZX-0792 ( neuraminidase )	流感病毒感染更多	终止
ZX-0610 ( neuraminidase )	流感病毒感染更多	终止
ZX-1291 ( ACE )	单纯疱疹更多	终止
ZX-1293 ( ACE )	单纯疱疹更多	终止
ZX-0620 ( neuraminidase )	流感病毒感染更多	终止